EI
FATE icon

EAM Investors’s Fate Therapeutics FATE Stock Holding History

EAM Investors’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-23,209
Closed -$2.11M – 371
2020
Q4 		$2.11M Sell
23,209
-12,951
-36% -$804K 0.35% 102
2020
Q3 		$1.45M Sell
36,160
-13,950
-28% -$487K 0.34% 120
2020
Q2 		$1.72M Sell
50,110
-17,537
-26% -$523K 0.38% 121
2020
Q1 		$1.5M Buy
+67,647
New +$1.71M 0.47% 101
2019
Q4 		– Sell
-38,540
Closed -$599K – 263
2019
Q3 		$599K Sell
38,540
-32,259
-46% -$618K 0.16% 223
2019
Q2 		$1.44M Hold
70,799
– – 0.35% 136
2019
Q1 		$1.24M Sell
70,799
-8,917
-11% -$141K 0.31% 152
2018
Q4 		$1.02M Sell
79,716
-2,027
-2% -$28.3K 0.28% 166
2018
Q3 		$1.33M Buy
81,743
+20,062
+33% +$237K 0.2% 181
2018
Q2 		$699K Sell
61,681
-217,480
-78% -$2.4M 0.11% 256
2018
Q1 		$2.73M Buy
+279,161
New +$2.67M 0.45% 113

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EAM Investors's FATE Position: Q1 2021 in Review

EAM Investors sold out of Fate Therapeutics (FATE) in Q1 2021, closing a stake of 23,209 shares — an estimated $2.11M sold.

EAM Investors first reported a position in FATE in Q1 2018 and held it in 11 quarters. The position peaked at $2.73M in Q1 2018. 260 funds tracked by Wall St. Rank hold FATE as of Q1 2021.

  • EAM Investors reported no remaining Fate Therapeutics position as of Q1 2021 after selling out during the quarter.
  • EAM Investors sold 23,209 Fate Therapeutics shares in Q1 2021, an estimated $2.11M.
  • EAM Investors first reported a position in Fate Therapeutics in Q1 2018 and held it in 11 quarters.
  • EAM Investors's Fate Therapeutics position peaked at $2.73M in Q1 2018.
  • 260 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2021.

Based on EAM Investors's 13F filing for Q1 2021, filed 11 May 2021.